This content is machine translated CDK4/6 inhibitors New class of drugs for breast cancer Adding the CDK4/6 inhibitor ribociclib to letrozole improved progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported at the ESMO 2016 Congress in Copenhagen.
